Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


The antibiotic paradox: why companies can’t afford to create life-saving drugs

A doctor listens to the lungs of a patient with tuberculosis with a stethoscope

A patient in South Africa battles a strain of tuberculosis that is resistant to multiple antibiotics. Drug resistance is a growing problem with many diseases. Credit: Joao Silva/NYT/Redux/eyevine

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature 584, 338-341 (2020)



  1. DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. J. Health Econ. 47, 20–33 (2016).

    Article  PubMed  Google Scholar 

  2. Shlaes, D. M. Antimicrob. Agents Chemother. 64, e02057-19 (2020).

    Article  Google Scholar 

  3. Clancy, C. J. & Nguyen, M. H. Antimicrob. Agents Chemother. 63, e01733-19 (2019).

    Article  Google Scholar 

  4. Clancy, C. J., Potoski, B. A., Buehrle, D. & Nguyen, M. H. Open Forum Infect. Dis. 6, ofz344 (2019).

    Article  PubMed  Google Scholar 

  5. Chen, N. et al. Lancet 395, 507–513 (2020).

    Article  PubMed  Google Scholar 

  6. Zhou, F. et al. Lancet 395, 1054–1062 (2020).

    Article  PubMed  Google Scholar 

  7. Rawson, T. A., Ming, D., Ahmad, R., Moore, L. S. P. & Holmes, A. H. Nature Rev. Microbiol. 18, 409–410 (2020).

    Article  PubMed  Google Scholar 

Download references


Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links